ReviewDiagnostics (Basel, Switzerland)2025
Recent Advances in Magnetic Resonance Imaging for the Diagnosis of Liver Cancer: A Comprehensive Review.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Theranostic Smart Bionanosensors for Solid Tumors: Advances, Challenges, and Future Directions.Applied biochemistry and biotechnology · 2026Review
- Hybrid FeInternational journal of molecular sciences · 2026Article
- Liquid Biopsy-Based Profiling ofInternational journal of hepatology · 2026Article
- Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRI is a non-invasive imaging technique employed today in modern diagnostic medicine due to the fact it is capable of generating tissue architecture and function information with high image resolution without the use of ionizing radiation, unlike x-ray or CT scans. The advantages of MRI discussed in this review include better soft tissue contrast, the opportunity to perform imaging in different planes, and the ability to detect small changes in tissues, which helps to use MRI in many specialties, including cancer diagnosis and staging, as well as neurological and cardiovascular diseases. More particularly, this review aims to assess the contribution of MRI to the detection of liver cancer, especially HCC and ICC-the most frequent and aggressive types of pathology. Because of its high-resolution, MRI provides clear visualization of the small hepatic lesion and vascular mapping, which is crucial for early diagnosis and staging. It also reveals higher sensitivity and specificity than ultrasound and CT in identifying liver cancer dimensions and relations with system vasculature and a safer technique for patients who need many follow-up images. This is in addition to newer techniques that have been developed from MRI, which include the DWI, DCE-MRI, and MRE, all of which yield functional information concerning the perfusion of the tumor and the stiffness of the tissue, respectively, thus improving the diagnosis. Moreover, the application of artificial intelligence to MRI is improving lesion identification and cancer assessment, as well as patient outcome prediction, while relieving the burden of radiologists. Suggested improvements for future work include the combination of MRI with other diagnostic approaches, including circulating cell analysis and molecular imaging in managing liver cancer. Still, there is a limitation in MRI's access globally, because scanners are expensive and unavailable in some parts of the world. Technological improvements and greater availability will extend MRI more as a valuable modality in the treatment of liver malignancies, more so for diagnosis and staging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.